Advancing research on Blastocystis through a One Health approach
Anastasios D. Tsaousis, Eleni Gentekaki, Christen Rune Stensvold
Abstract
<ns3:p> <ns3:italic>Blastocystis</ns3:italic> is the most prevalent intestinal eukaryotic microorganism with significant impacts on both human and animal health. Despite extensive research, its pathogenicity remains controversial. The COST Action CA21105, " <ns3:italic>Blastocystis</ns3:italic> under One Health" (OneHealthBlastocystis), aims to bridge gaps in our understanding by fostering a multidisciplinary network. This initiative focuses on developing standardised diagnostic methodologies, establishing a comprehensive subtype and microbiome databank, and promoting capacity building through education and collaboration. The Action is structured into five working groups, each targeting specific aspects of <ns3:italic>Blastocystis</ns3:italic> research, including epidemiology, diagnostics, 'omics technologies, <ns3:italic>in vivo</ns3:italic> and <ns3:italic>in vitro</ns3:italic> investigations, and data dissemination. By integrating advances across medical, veterinary, public, and environmental health, this initiative seeks to harmonise diagnostics, improve public health policies, and foster innovative research, ultimately enhancing our understanding of <ns3:italic>Blastocystis</ns3:italic> and its role in health and disease. This collaborative effort is expected to lead to significant advancements and practical applications, benefiting the scientific community and public health. </ns3:p>